相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
Laura Maria Fuhr et al.
PHARMACEUTICS (2021)
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib
Matthias Kroiss et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Alberto D'Angelo et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Daniel Castellano et al.
CANCER TREATMENT REVIEWS (2020)
Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation
Colleen Kuemmel et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
Emma D. Deeks
TARGETED ONCOLOGY (2019)
Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro
Qian-meng Lin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2019)
A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients
Vanessa Baier et al.
FRONTIERS IN PHYSIOLOGY (2019)
New Insights About Albumin and Liver Disease
Joana R. Carvalho et al.
ANNALS OF HEPATOLOGY (2018)
A sensitive LC-MS/MS method for simultaneous determination of cabozantinib and its metabolite cabozantinib N-oxide in rat plasma and its application in a pharmacokinetic study
Lian-jie Ren et al.
BIOMEDICAL CHROMATOGRAPHY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
Jordan N. Markowitz et al.
PHARMACOTHERAPY (2018)
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
Nina Hanke et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
US Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Harpreet Singh et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
Steven A. Lacy et al.
CLINICAL PHARMACOKINETICS (2017)
Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case
Roberto Andrea Abbiati et al.
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH (2017)
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Nizar M. Tannir et al.
CURRENT ONCOLOGY REPORTS (2017)
Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis
Dale Miles et al.
CLINICAL PHARMACOKINETICS (2016)
Albumin in chronic liver disease: structure, functions and therapeutic implications
Rosaria Spinella et al.
HEPATOLOGY INTERNATIONAL (2016)
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Claudia Neul et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
L. Kuepfer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Cabozantinib in Thyroid Cancer
Poupak Fallahi et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2015)
Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites
Steven Lacy et al.
DRUG METABOLISM AND DISPOSITION (2015)
Species differences in drug plasma protein binding
Nicola Colclough et al.
MEDCHEMCOMM (2014)
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer
Sravanthi Cheeti et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Alfred H. Schinkel et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry
Anand K. Deo et al.
DRUG METABOLISM AND DISPOSITION (2012)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks
Thomas Eissing et al.
FRONTIERS IN PHYSIOLOGY (2011)
A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
A Quantitative Enterohepatic Circulation Model Development and Evaluation with Tesofensine and Meloxicam
Thorsten Lehr et al.
CLINICAL PHARMACOKINETICS (2009)
Physiology-Based Simulations of a Pathological Condition Prediction of Pharmacokinetics in Patients with Liver Cirrhosis
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2008)
Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents
Aldo D. Mottino et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function
Yukiko Metsugi et al.
PHARMACEUTICAL RESEARCH (2008)
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
Marcella Martignoni et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Hepatobiliary transporters and drug-induced cholestasis
Christiane Pauli-Magnus et al.
HEPATOLOGY (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones et al.
CLINICAL PHARMACOKINETICS (2006)
Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition
Gabriele Jedlitschky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma
FA Brightman et al.
DRUG METABOLISM AND DISPOSITION (2006)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Enterohepatic bile salt transporters in normal physiology and liver disease
GA Kullak-Ublick et al.
GASTROENTEROLOGY (2004)
Enterohepatic circulation - Physiological, pharmacokinetic and clinical implications
MS Roberts et al.
CLINICAL PHARMACOKINETICS (2002)
Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis
M Oswald et al.
LIVER (2001)
Up-regulation of transporters of the MRP family by drugs and toxins
D Schrenk et al.
TOXICOLOGY LETTERS (2001)
分享论文
